MRUS
Merus N.V
$27.20
-0.02 (-0.07%)
quotes and stock data delayed 15 minutes
52 wk hi
52 wk low
10.5
30.59
Cash
$190.2M
Burn Rate (Qtr)
$11.7M
Mkt Cap
$859.6m
Avg Volume
216,823
*cash/burn updated:
Q3'20
Company Profile
Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have similar features as conventional monoclonal antibodies, such as long half-life and low immunogenicity.
Drug Pipeline
Click on drug name or indication to see upcoming trial info, prior data, and more general information
Drug | Disease (links)
Stage (next event)
Catalyst Date
Recent Posts
See what the community is saying - click to see full post